The complaint, filed by The Gross Law Firm, targets a class period spanning from August 9, 2024, to March 25, 2026. Plaintiffs allege that the company artificially inflated its financial standing through channel stuffing—the practice of inflating sales figures by sending excess inventory to distributors. The lawsuit further claims that ADMA Biologics failed to maintain adequate internal controls and concealed a significant related-party transaction, rendering public statements about the firm's business prospects materially false.
In section Releases
Investors Face August Deadline in ADMA Biologics Securities Suit
Shareholders of ADMA Biologics, Inc. have until August 10, 2026, to seek lead plaintiff status in a pending class action lawsuit. The litigation centers on allegations that the biopharmaceutical company misled investors regarding its revenue practices, internal controls, and undisclosed related-party transactions throughout a nearly two-year period.
Investors who purchased ADMA shares during the designated window may participate in the recovery efforts without an upfront cost. While the August 10 deadline specifically applies to those wishing to serve as lead plaintiff, the firm is currently enrolling shareholders in portfolio monitoring programs to track the case's progress. Interested parties can submit their information through the firm's legal portal to secure representation or receive case updates.
Comments (0)
No comments yet. Be the first!